Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
A new indication has been added to the product information for baricitinib. In addition to rheumatoid arthritis and atopic dermatitis, baricitinib is now also approved for the treatment of severe alopecia areata. This therapy…
Read more
The tablet presentation of acalabrutinib has recently been added to the Pharmaceutical Benefits Scheme (PBS). Acalabrutinib is also available in a capsule and is PBS-subsidised for the treatment of relapsed or refractory chronic lymphocytic…
Read more
The Topamax® (topiramate) product information has recently been updated. When used for migraine prophylaxis, this medicine is now contraindicated in pregnancy and in women of childbearing potential unless a highly effective method of contraception is…
Read more
The Pharmaceutical Benefits Scheme (PBS) listings for pembrolizumab and lenvatinib have been expanded. These agents are now listed for use in combination to treat advanced, metastatic, or recurrent endometrial carcinoma. The safety and efficacy…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for apalutamide has been expanded to include metastatic castration-sensitive prostate cancer. Apalutamide is an androgen receptor inhibitor. It can reduce tumour volume by decreasing tumour cell proliferation and…
Read more
The Therapeutic Goods Administration (TGA) has published a Medicines Safety Update for the Janus kinase (JAK) inhibitors, tofacitinib, baricitinib and upadacitinib. This update relates to the findings of the ORAL Surveillance study, a large,…
Read more
